Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 48 Equity-to-Asset is 0.36 as of Jun. 2026, which is 37% below its 10-year median of 0.57. GuruFocus rates CHIX:BOULS with a GF Score™ of 48/100 and a GF Value™ of kr52.09. The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 78.19% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Boule Diagnostics AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr174.9 Mil. Boule Diagnostics AB's Total Assets for the quarter that ended in Jun. 2026 was kr480.8 Mil.
Therefore, Boule Diagnostics AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.36.
The historical rank and industry rank for Boule Diagnostics AB's Equity-to-Asset or its related term are showing as below:
CHIX:BOULs'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35 Med: 0.57 Max: 0.69
Current: 0.37
During the past 13 years, the highest Equity to Asset Ratio of Boule Diagnostics AB was 0.69. The lowest was 0.35. And the median was 0.57.
CHIX:BOULs's Equity-to-Asset is ranked worse than 78.19% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs CHIX:BOULs: 0.37
Boule Diagnostics AB (CHIX:BOULs) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Boule Diagnostics AB Equity-to-Asset Related Terms
Boule Diagnostics AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Boule Diagnostics AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (CHIX:BOULS) has a Equity-to-Asset of 0.36 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Boule Diagnostics AB and its competitors. This is 37% below median its historical median of 0.57. Over the past decade, Boule Diagnostics AB's Equity-to-Asset has ranged from 0.35 to 0.69. According to the industry distribution chart, Boule Diagnostics AB ranks #667 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 78.2%.
Is Boule Diagnostics AB's Equity-to-Asset too high?
Boule Diagnostics AB's current Equity-to-Asset of 0.36 is 37% below median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.69. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Boule Diagnostics AB's value of 0.36 is 44.6% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #667 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #667 out of 853 companies for Equity-to-Asset. This places Boule Diagnostics AB in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Boule Diagnostics AB's value of 0.36 is 44.6% below this benchmark. Historically, Boule Diagnostics AB's own Equity-to-Asset has ranged from 0.35 to 0.69 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 0.65, Boule Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Equity-to-Asset of 0.36 is 44.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Equity-to-Asset is 0.36, which is 37% below median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Equity-to-Asset of 0.36. The stock's GF Value™ is kr52.09, compared to a current price of kr26.30 — trading 49.5% below its estimated fair value. The current Equity-to-Asset is 0.36, which is 37% below median its 10-year median of 0.57 and 44.6% below the Medical Devices & Instruments industry median of 0.65. Boule Diagnostics AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Equity-to-Asset is 0.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 49.5% below its estimated GF Value™ of kr52.09.
Key valuation signals for CHIX:BOULS:
Equity-to-Asset: 0.36 (37% below median its 10-year median of 0.57)
GF Value™: kr52.09 vs. price of kr26.30 (49.5% below fair value)
Industry Position: 44.6% below the Medical Devices & Instruments median (#667 of 853)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
48GF Score
Get the complete analysis for CHIX:BOULS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
